Sign up today for an exclusive discount along with our 30-day GUARANTEE — Love us or leave, with your money back! Click here to become a part of our growing community and learn how to stop gambling with your investments. We will teach you to BE THE HOUSE — Not the Gambler!

Click here to see some testimonials from our members!

Stocks Surge On Moderna Vaccine News Redux

Courtesy of ZeroHedge View original post here.

US equity markets are higher after-hours following news that Moderna’s potential COVID-19 vaccine produced immune responses in patients in the early stage trial, according to results published in a peer-reviewed journal for the first time.

The US biotech company’s vaccine candidate produced antibodies in all 45 participants in the first cohort of the phase one trial run by the National Institutes of Health, while the paper said there were no safety problems that could curtail further trials. 

On May 18th we were told the headlines on this trial (on 8 patients)… this is the details of that study on the full 45 patients

METHODS

We conducted a phase 1, dose-escalation, open-label trial including 45 healthy adults, 18 to 55 years of age, who received two vaccinations, 28 days apart, with mRNA-1273 in a dose of 25 μg, 100 μg, or 250 μg. There were 15 participants in each dose group.

CONCLUSIONS

The mRNA-1273 vaccine induced anti–SARS-CoV-2 immune responses in all participants, and no trial-limiting safety concerns were identified. These findings support further development of this vaccine.

As The FT reports, Tal Zaks, chief medical officer at Moderna, said the vaccine candidate — known as mRNA-1273 — elicits a “robust immune response across all dose levels”.

“We look forward to beginning our Phase three study of mRNA-1273 this month to demonstrate our vaccine’s ability to significantly reduce the risk of Covid-19 disease,” he said.

As a reminder, Moderna was the first US company to test its potential vaccine in humans, sending the vials to the NIH just 42 days after it received the genome of Covid-19. It has received $483m in funding from the US Biomedical Advanced Research and Development Agency to speed up the development of the vaccine.

The broad market is spiking on this old news…

MRNA is also soaring…

Who leaked this news yesterday?

Which we humbly suggest will be an insider-selling opportunity

Remember what happened last time!


Do you know someone who would benefit from this information? We can send your friend a strictly confidential, one-time email telling them about this information. Your privacy and your friend's privacy is your business... no spam! Click here and tell a friend!





You must be logged in to make a comment.
You can sign up for a membership or get a FREE Daily News membership or log in

Sign up today for an exclusive discount along with our 30-day GUARANTEE — Love us or leave, with your money back! Click here to become a part of our growing community and learn how to stop gambling with your investments. We will teach you to BE THE HOUSE — Not the Gambler!

Click here to see some testimonials from our members!